Sertindole: dilemmas for its use in clinical practice

Bibliography

• Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010;71:1115-24
   PubMed Web of Science ®Google Scholar
• Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005;66(Suppl 6):5-10
   PubMedGoogle Scholar
• Karamatskos E, Lambert M, Mulert C, Drug safety and efficacy evaluation of sertindole for schizophrenia. Expert Opin Drug Saf 2012;11:1047-62
   PubMed Web of Science ®Google Scholar
• Nielsen J, Graff C, Kanters JK, Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011;25:473-90
   PubMed Web of Science ®Google Scholar
• Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med 2012;43:906-13
   PubMed Web of Science ®Google Scholar
• Harrigan EP, Miceli JJ, Anziano R, A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9
   PubMed Web of Science ®Google Scholar
• Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71
   PubMed Web of Science ®Google Scholar
• Nielsen J, Andersen MP, Graff C, The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010;121:385-8
   PubMed Web of Science ®Google Scholar
• Nielsen J, Graff C, Hardahl T, Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009;19:702-7
   PubMed Web of Science ®Google Scholar
• Thomas SH, Drici MD, Hall GC, Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010;122:345-55
   PubMed Web of Science ®Google Scholar
• Hertz S. NDA file. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM234349.pdf [Accessed on 22 November 2010]
   Google Scholar
• Ray WA, Chung CP, Murray KT, Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
   PubMed Web of Science ®Google Scholar
• Drug Information Association. Suicidality Indication & Safety Profile for Lundbeck's Schizophrenia Drug Not Supported. Available from: http://www.diahome.org, 2009
   Google Scholar
• Kasper S, Moller HJ, Hale A. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010;260:59-68
   PubMed Web of Science ®Google Scholar
• van Kammen DP, McEvoy JP, Targum SD, A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:168-75
   PubMed Web of Science ®Google Scholar
• Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 1998;13(Suppl 3):S65-70
   PubMedGoogle Scholar
• Daniel DG, Wozniak P, Mack RJ, Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998;34:61-9
   PubMed Web of Science ®Google Scholar
• Zimbroff DL, Kane JM, Tamminga CA, Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 1997;154:782-91
   PubMed Web of Science ®Google Scholar
• Kane JM, Potkin SG, Daniel DG, A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry 2011;72:194-204
   PubMed Web of Science ®Google Scholar
• Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006;21:49-56
   PubMed Web of Science ®Google Scholar
• Kwon JS, Mittoux A, Hwang JY, The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study. Int Clin Psychopharmacol 2012;27:326-35
   PubMed Web of Science ®Google Scholar
• Leucht S, Arbter D, Engel RR, How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009;14:429-47
   PubMed Web of Science ®Google Scholar
• Lundbeck. Serdolect® (Sertindole) Tablets for Treatment of Schizophrenia. United States Food and Drug Psychopharmacologic Drugs Advisory Committee (Eds); 2009
   Google Scholar
• U.S. Food and Drug Administration. Available from: http://www.fda.gov [Accessed 13 November 2012]
   Google Scholar
• Hashimoto Y, Uno J, Miwa T, Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients. Psychiatry Clin Neurosci 2012;66:405-10
   PubMed Web of Science ®Google Scholar
• Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2006;45:957-64
   PubMed Web of Science ®Google Scholar
• Gallego JA, Bonetti J, Zhang J, Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012;138:18-28
   PubMed Web of Science ®Google Scholar
• Goff DC, Freudenreich O. Focus on polypharmacy in schizophrenia: does anyone truly benefit? Int J Neuropsychopharmacol 2004;7:109-11
   PubMed Web of Science ®Google Scholar
• Stahl SM. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol 2004;7:113-16
   PubMed Web of Science ®Google Scholar
• Sala M, Vicentini A, Brambilla P, QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005;4:1
   PubMedGoogle Scholar
• Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004;18(Suppl 2):19-30, discussion 41-3
   PubMed Web of Science ®Google Scholar
• Vieweg WV, Wood MA, Fernandez A, Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009;26:997-1012
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health (UK). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (Update). National Institute for Health and Clinical Excellence (NICE), Leicester, UK; 2009
   Google Scholar
• Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567-620
   PubMed Web of Science ®Google Scholar
• Vieweg WV, Hasnain M, Howland RH, Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012;125:859-68
   PubMed Web of Science ®Google Scholar
• Chung CP, Murray KT, Stein CM, A computer case definition for sudden cardiac death. Pharmacoepidemiol Drug Saf 2010;19:563-72
   PubMed Web of Science ®Google Scholar
• Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf 2009;8:373-86
   PubMed Web of Science ®Google Scholar